+ Watch CRTX
on My Watchlist
A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.
My old college dorm was voted "Most apathetic" in a student survey, so we all got T-shirts that said "Everyone says we're apathetic, but we don't care." That's pretty much how I feel about Cornerstone. I care just enough to drop a green thumb and a pitch.Cornerstone is a good candidate for a rebound if broad market parameters improve. Revenues have been stable and the bottom line will benefit from sales of Spectracef and Factive. Impending approval of generic Tussionex may provide another boost. CAPS only, 5-10 points and out.
Upcoming week will be huge runs for NAVB after expected FDA approval, CRTX's positive panel votes, AMRN's NCE status 5 years announcement. Good luck to all.
Wow, zero for three. You might be ready to inherit Rodman & Renshaw's title as king of the biopharma contrarian indicators.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions